Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 1046Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 Table of Contents      
Year : 2015  |  Volume : 6  |  Issue : 4  |  Page : 179-183

Clinical data acquisition standards harmonization importance and benefits in clinical data management

Domain Consultant, Life Sciences, Tata Consultancy Services, Mumbai, Maharashtra, India

Date of Web Publication12-Oct-2015

Correspondence Address:
Jagadeeswara Rao Gaddale
S-2, Brundavana Apartments, 2nd Cross, Patellappa Layout, Nagashettyhalli, Bengaluru - 560 094, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2229-3485.167101

Rights and Permissions

In the clinical trial process, precise and concise data collection at the source is imperative and requires statistical analysis to be performed to derive the primary and secondary endpoints. The quality of raw data collection has a direct impact on the statistical outputs generated as per the statistical analysis plan. Hence, the data collection tools used for data transcription must be clear, understandable, and precise, which helps the investigator to provide the accurate subject data. Clinical Data Acquisition Standards Harmonization (CDASH) provides guidance to develop the case report form (CRF) for domains that are commonly used for the majority of the clinical trials across the therapeutic areas. This white paper describes the importance of CDASH standards, its advantages and its impact on the efforts and the cost in designing the CRF.

Keywords: Clinical Data Acquisition Standards Harmonization, clinical data interchange standards consortium, data standards, Study Data Tabulation Model

How to cite this article:
Gaddale JR. Clinical data acquisition standards harmonization importance and benefits in clinical data management. Perspect Clin Res 2015;6:179-83

How to cite this URL:
Gaddale JR. Clinical data acquisition standards harmonization importance and benefits in clinical data management. Perspect Clin Res [serial online] 2015 [cited 2023 Feb 8];6:179-83. Available from: http://www.picronline.org/text.asp?2015/6/4/179/167101

   Introduction Top

Post the successful completion of laboratory trials, new chemical entities, and new drug formulations are tested in human beings through Phase I–IV studies to assess their safety and efficacy before providing market approval. The study procedures vary from protocol to protocol and prequalified principal investigators conducts the trials at research centers and collect the required data on source documents at multiple visits as per the protocol. The data comprises of subject demographics, habits, medications taken, events, study procedures, test drug usage, etc., These data are called as source data and are a part of hospital records.

The principal investigators transcribe the required trial data onto the case report form (CRF) either in electronic or paper format provided by the sponsor or Clinical Research Organizations (CROs).

The clinical data manager develops the CRF with the help of the statistician, clinical operations team, the medical monitor, and the sponsor before subject enrollment and provides adequate training to the site personnel to complete the CRF as per the requirements.

While designing the CRF, the clinical data manager understands the protocol thoroughly and includes the CRF pages/forms as per the scheduled visits by following sponsor standards or those developed internally. Clinical Data Acquisition Standards Harmonization (CDASH) describes common best practices to develop CRFs instead of following one's own standards. These standards are extensively recommended by regulatory bodies like the Food and Drug Administration (FDA).[1]

   Clinical Data Acquisition Standards Harmonization Top

The intent of CDASH is to develop content standards for basic set of global CRF fields. These are global CRF standards that apply for all therapeutic area (TA) across phases.


The CDASH standard is part of the clinical data interchange standards consortium (CDISC) initiative. CDSIC initiated work on CDASH standards in October 2006. The teams consisted of clinical data managers, statisticians, medical monitors, and programmers, and they collected data from clinical trial sites with the help of groups like Society of Clinical Data Management, National Cancer Institute, Association of CROs, FDA, CDISC, Critical Path Institute, Cancer Biomedical Informatics Grid, etc., Three International Conference on Harmonization regions – USA, Europe, and Japan have been covered while collecting the data and suggestions. The consolidated first draft has been posted in May 2008 for review.

The CDASH version 1.0 has been released by CDISC in October 2008, subsequently version 1.1 has been posted in January 2011. The version 2.0 is scheduled to be released in 2015.[2]

Clinical Data Acquisition Standards Harmonization standard domains

CDASH classifies different types of data collection fields as:

  • Highly recommended (HR) - A data collection field that should be on the CRF (e.g. a regulatory requirement)
  • Recommended/conditional (R/C) - A data collection field that should be on a CRF based on certain conditions (e.g. complete date of birth is preferred but may not be allowed in some regions; AE time should only be captured if there is another data point with which to compare)
  • Optional (O) - A data collection field that is available for use.[3]

Study Data Tabulation Model (SDTM) has been considered as a base to develop the contents. The latest version CDASH 1.1 describes the contents for 16 standard domains as outlined [Figure 1].[3]
Figure 1: CDASH standard domains

Click here to view

CDASH delivers the field name, prompt, use of the field, guidelines to fill the field, and its recommendation for the 16 domains in the format provided [Table 1].
Table 1: CDASH domain tables structure

Click here to view

The metadata of CDASH represents the part of Operational Data Model for any regulatory submission.[3]

   Benefits of Using Clinical Data Acquisition Standards Harmonization Standard Case Report Forms Top

The design of the database in SDTM is critical for regulatory data submissions. The raw data in SDTM format help in creating the common technical document (CTD) submissions and also helps to create Analysis Dataset Model (ADaM) datasets with minimum programming efforts. As the CDASH standards are a subset of SDTM, initiating the data collection at source smoothens the entire data path, and no redundancy of data collection happens throughout the study.

CDASH highly recommends capturing only key data that are required for statistical analysis. This approach eliminates a few CRF fields; for example, the collection of “yes/no” answers for inclusion/exclusion (IE) criteria CRF. CDASH describes that the IE criteria are at a study level, and it is not necessary to collect this information for each subject. Instead, CDASH recommends collecting only the unmet criterion for which the deviation has been approved by the stakeholders. [Figure 2] is the example of nonstandard CRF versus CDASH CRF.[3]
Figure 2: Traditional case report form for inclusion and exclusion criteria

Click here to view

Similarly, CDASH recommends to collect the physical examination test status instead of collecting the data for each body system as any abnormality should be either part of “medical history” or “adverse event” CRF. Thus, CDASH standards avoid duplicate data collection by eliminating some variety of CRFs [Figure 3].
Figure 3: Traditional physical examination page

Click here to view

The above CRF:

  • Eliminates collection and reconciliation of duplicate data by capturing abnormal data in one central location
  • Reduces number of queries, thus reducing workload for data managers and site personnel
  • Supports consistency and standardization for data reporting purposes
  • Reduces coding needs (if PE abnormalities are coded).

CDASH Standards improve the common understanding across the clinical trial stakeholders and yield better quality data, reduce data queries and facilitate efficient SDTM mapping for regulatory submissions.[4]

Challenges in implementing Clinical Data Acquisition Standards Harmonization standards

The majority of the Clinical Data Management System (CDMS)/Electronic Data Capture (EDC) tools such as Medidata Rave, Oracle Clinical and Oracle Remote Data Capture, inform, and ClinPlus support CDASH electronic CRF development. Sometimes, the implementation may need customized programming, especially while data integration between lab data, electronic patient reported outcome, interactive web response system, and EDC. The requirements vary based on the complexity and the study procedures.[5]

Adapting to CDASH standards for long-term trials that are on-going is a potential challenge. A customized approach is needed to map the data points. For example, shifting mid-ways during the study to CDASH standards on a 5-year trial that is being conducted per sponsor standards is challenging During this migration, a lot of effort would need to be invested in document generation, mapping of fields with currently available fields and various other activities. So it is recommended that the decision on which data standards should be used should be made up front.

Similarly, mapping of legacy trial data to CDASH standards also requires a customized approach.

   Clinical Data Acquisition Standards Harmonization Implementation: Impact on Cost and Analysis Top

The accurate and targeted design of simple to use CRFs with clear CRF completion guidelines is crucial as a part of the study start-up activities for a protocol. The draft CRF is reviewed by the study stakeholders including clinical research associates, data managers, medical monitors, and statisticians. The approved CRF is the source for the programmers to configure the CRF in the EDC tools or CDMS tools that are deployed for the study protocol. Usually, it takes 2–3 months to design the CRF and make the database live for data entry.[6]

The CDASH domain CRFs can be used across studies, across the industry with no limitation of TAs. One time efforts in generating the repository of CDASH defined CRFs can be utilized for multiple studies: thus time and efforts are minimized which in turn enables a reduction of the operational cost with respective to study start up activities.

CDASH guidelines specify details of domain and its corresponding variable definitions. These comprise of variable name, definition, instructions to clinical sites, implementation, and core configuration. The core configuration describes whether the variable is highly recommended, recommended/conditional or optional. However, CDASH does not specify length, order, and contents of variables. CDASH does not specify code lists but refers to SDTM terminology, and they recommend terms where code lists are not listed in SDTM Implementation guide.[7]

The impact of Clinical Data Acquisition Standards Harmonization on full-time equivalent utilization and cost: Estimate and analysis

Assume that there are 10 multiple TA studies with 60 CRF pages per study for each subject, of which 25 are unique CRFs. The CRFs and edit check specifications can be finalized in accordance with client specific standards, CRO standards (SOPs) or CDASH standards.

By implementing the CDASH standards, the number of hours spent for CRF development, edit check specifications, programming screens, edits, and SDTM mapping will be reduced. The review efforts on CRFs and completion guidelines by other study stakeholders are also minimized with the CDASH standards implementation. There will be a significant reduction (~60%) in full-time equivalent utilization which in turn reduces the operational cost and improvise the efficiency proportionately. Savings reaped, the cost of implementation and return on investment of standards will vary depending on various factors.

  • Existing use of proprietary standards
  • Stage of implementation.

    • Start-up stage (~70–90% savings)
    • Study conduct (~40% savings)
    • Analysis and reporting (~50% savings)
    • Overall (~60% savings).[8]
Regulatory submission requirements

The reviewers at regulatory bodies analyze the clinical trial data submitted by the pharma and biotech companies. It takes approximately 18 months for the review of nonstandard data submission models. The FDA recommends submitting the data in CDSIC standardized formats. This fastens the review process as the regulators can reuse their programs if the data is present in a standard datasets.[4]

As per the regulatory requirements, the implementation of CDISC standards from the initial stages is highly beneficial for pharma and biotech companies and also helps in the faster review process by FDA.[4]

The CDISC standardization path:


   Conclusion Top

There are many benefits to be gained if the clinical research industry adapts to data standards especially CDISC standards. Technology companies providing data collection tools should leverage the benefits of data standards and should optimize operational cost. Pharma companies spend more money on following their own standards while developing the CRFs and designing the databases in the EDC/CDMS tools. This approach again needs data conversion techniques for regulatory submissions. As a common goal, it is highly recommended to initiate and implement the CDISC standardization path that provides the benefits of cost, time and high accuracy of data. At the same time, CDASH standards act as a catalyst to reduce the turnaround time for the review process and helps companies to launch drugs in the markets. In the case of orphan drugs and fast track drugs, the implementation of standards is imperative in reducing the time required in bringing the drug to the market.


I would like to express my sincere thanks to Dr. Nimita Limaye, VP, CDM, Medical Writing and Risk Based Monitoring, Tata Consultancy Services for reviewing the article ad providing guidance and insights.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

FDA. Available from: http://www.fda.gov/. [Last accessed on 2015 May 10]  Back to cited text no. 1
CDISC. Available from: http://www.cdisc.org/cdash. [Last accessed on 2015 May 10]  Back to cited text no. 2
CDASH Version 1.1 Implementation Guide. [Last accessed on 2015 May 10]  Back to cited text no. 3
Ben Vali MS., The Importance of CDASH. Available from: http://www.cdisc.org/system/files/all/generic/application/pdf/vali_the_importance_of_cdash.pdf. [Last accessed 2015 Jun 2].  Back to cited text no. 4
Linger RS. Implementing CDASH Standards into Data Collection and Database Design. Available from: http://www.portal.cdisc.org/CDISC20User20Networks/North20America/Bay20Area/Presentations/Meeting2010110920-20Implementing20CDASH20Standards20-20Robert20Stemplinger.pdf.; [Last accessed 2015 Jun 2].  Back to cited text no. 5
De Bondt J. CDASH: A Must for EDC Trials. Available from: http://www.sgs.com/~/media/Global/Documents/Technical%20Documents/SGS-Clinical-CDASH-EN-11.pdf. [Last Accessed 2015 Jun 2].  Back to cited text no. 6
Price J. A Practical Introduction to Clinical Data Acquisition Standards Harmonization (CDASH). Available from: http://www.bioclinica.com/assets/Uploads/a-practical-introduction-to-cdash.pdf. [Last Accessed 2015 Jun 2].  Back to cited text no. 7
Business Case for CDISC Standards: Summary; PhRMA-Gartner-CDISC Project; September, 2006. Available from: http://www.cdisc.org/system/files/all/article/application/pdf/businesscasesummarywebmar09.pdf. [Last accessed 2015 May 10].  Back to cited text no. 8


  [Figure 1], [Figure 2], [Figure 3]

  [Table 1]

This article has been cited by
1 Perpetual Observational Studies: New strategies to support efficient implementation of observational studies and randomized trials in infectious diseases
N. Hassoun-Kheir, C.H. van Werkhoven, J. Dunning, T. Jaenisch, J. van Beek, J. Bielicki, C. Butler Prof, B. Francois, S. Harbarth Prof, A. C. Hernandez Padilla, P. Horby Prof, M. Koopmans Prof, J. Lee, J. Rodriguez-Baño Prof, E. Tacconelli Prof, Y. Themistocleous, A.W. van der Velden, M. Bonten Prof, H. Goossens Prof, M.E.A. de Kraker
Clinical Microbiology and Infection. 2022;
[Pubmed] | [DOI]
2 Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders
Anthony L. Vaccarino, Derek Beaton, Sandra E. Black, Pierre Blier, Farnak Farzan, Elizabeth Finger, Jane A. Foster, Morris Freedman, Benicio N. Frey, Susan Gilbert Evans, Keith Ho, Mojib Javadi, Sidney H. Kennedy, Raymond W. Lam, Anthony E. Lang, Bianca Lasalandra, Sara Latour, Mario Masellis, Roumen V. Milev, Daniel J. Müller, Douglas P. Munoz, Sagar V. Parikh, Franca Placenza, Susan Rotzinger, Claudio N. Soares, Alana Sparks, Stephen C. Strother, Richard H. Swartz, Brian Tan, Maria Carmela Tartaglia, Valerie H. Taylor, Elizabeth Theriault, Gustavo Turecki, Rudolf Uher, Lorne Zinman, Kenneth R. Evans
Frontiers in Psychiatry. 2022; 13
[Pubmed] | [DOI]
3 TBDBT: A TB DataBase Template for collection of harmonized TB clinical research data in REDCap, facilitating data standardisation for inter-study comparison and meta-analyses
Taryn Allie,Amanda Jackson,Jon Ambler,Katherine Johnston,Elsa Du Bruyn,Charlotte Schultz,Linda Boloko,Sean Wasserman,Angharad Davis,Graeme Meintjes,Robert J. Wilkinson,Nicki Tiffin,Seyed Ehtesham Hasnain
PLOS ONE. 2021; 16(3): e0249165
[Pubmed] | [DOI]
4 An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia
Taniawati Supali,Yenny Djuardi,Michael Christian,Elisa Iskandar,Rahmat Alfian,Roospita Maylasari,Yossi Destani,Adriani Lomiga,Dominikus Minggu,Daphne Lew,Joshua Bogus,Gary J. Weil,Peter U. Fischer,Marc P. Hübner
PLOS Neglected Tropical Diseases. 2021; 15(3): e0009294
[Pubmed] | [DOI]
5 Pragmatic MDR: a metadata repository with bottom-up standardization of medical metadata through reuse
Stefan Hegselmann,Michael Storck,Sophia Gessner,Philipp Neuhaus,Julian Varghese,Philipp Bruland,Alexandra Meidt,Cornelia Mertens,Sarah Riepenhausen,Sonja Baier,Benedikt Stöcker,Jörg Henke,Carsten Oliver Schmidt,Martin Dugas
BMC Medical Informatics and Decision Making. 2021; 21(1)
[Pubmed] | [DOI]
6 The iCRF Generator: Generating interoperable electronic case report forms using online codebooks
Sander de Ridder,Jeroen A.M. Beliën
F1000Research. 2020; 9: 81
[Pubmed] | [DOI]
7 The iCRF Generator: Generating interoperable electronic case report forms using online codebooks
Sander de Ridder,Jeroen A.M. Beliën
F1000Research. 2020; 9: 81
[Pubmed] | [DOI]
8 Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study
Christine L. Dubray,Anita D. Sircar,Valery Madsen Beau de Rochars,Joshua Bogus,Abdel N. Direny,Jean Romuald Ernest,Carl R. Fayette,Charles W. Goss,Marisa Hast,Kobie O’Brian,Guy Emmanuel Pavilus,Daniel Frantz Sabin,Ryan E. Wiegand,Gary J. Weil,Jean Frantz Lemoine,Subash Babu
PLOS Neglected Tropical Diseases. 2020; 14(6): e0008298
[Pubmed] | [DOI]
9 Developing Real-world Evidence-Ready Datasets: Time for Clinician Engagement
James M. Snyder,Jacob A. Pawloski,Laila M. Poisson
Current Oncology Reports. 2020; 22(5)
[Pubmed] | [DOI]
10 Design of a “Lean” Case Report Form for Heart Failure Device Development
Mitchell A. Psotka,Mona Fiuzat,Peter E. Carson,David P. Kao,Jeffrey Cerkvenik,Daniel E. Schaber,Patrick Verta,Robert T. Kazmierski,Meir Shinnar,Norman Stockbridge,Ellis F. Unger,Bram Zuckerman,Javed Butler,G. Michael Felker,Marvin A. Konstam,JoAnn Lindenfeld,Scott D. Solomon,John R. Teerlink,Christopher M. OæConnor,William T. Abraham
JACC: Heart Failure. 2019;
[Pubmed] | [DOI]
11 EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases
Sophia von Martial,Tobias J. Brix,Luisa Klotz,Philipp Neuhaus,Klaus Berger,Clemens Warnke,Sven G. Meuth,Heinz Wiendl,Martin Dugas,Orhan Aktas
PLOS ONE. 2019; 14(10): e0223886
[Pubmed] | [DOI]
12 A Standard-driven Approach for Electronic Submission to Pharmaceutical Regulatory Authorities
Ching-Heáng Lin,Hsin-I Chou,Ueng-Cheng Yang
Journal of Biomedical Informatics. 2018;
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Clinical Data Ac...
    Benefits of Usin...
    Clinical Data Ac...
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded2010    
    Comments [Add]    
    Cited by others 12    

Recommend this journal